Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of risk

J Diabetes Complications. 2023 Nov;37(11):108628. doi: 10.1016/j.jdiacomp.2023.108628. Epub 2023 Oct 10.

Abstract

T2D is a well-established risk factor for development and progression of CKD. KDIGO recommends categorization of risk by likelihood of progression to ESKD. Compared to placebo, empagliflozin decreases likelihood of worsening (OR 0.70, 95 % CI 0.62-0.78) and increases likelihood of improvement (OR 1.56, 95 % CI 1.30-1.86) in KDIGO risk category.

Keywords: Diabetes complications; Diabetes treatment; Empagliflozin; KDIGO; SGLT2 inhibitor; T2D.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Kidney
  • Renal Insufficiency, Chronic* / complications
  • Renal Insufficiency, Chronic* / epidemiology
  • Renal Insufficiency, Chronic* / prevention & control
  • Risk Factors
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

  • empagliflozin
  • Sodium-Glucose Transporter 2 Inhibitors
  • Sodium-Glucose Transporter 2